NasdaqGM - Nasdaq Real Time Price USD

Avidity Biosciences, Inc. (RNA)

26.16
-0.10
(-0.38%)
As of 11:32:13 AM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for RNA

Recent News: RNA

View More
Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences to Participate in Upcoming Investor Conference
PR Newswire yesterday
Trump’s FDA Sends a Bullish Signal to Biotech

Trump’s FDA Sends a Bullish Signal to Biotech
The Wall Street Journal 15 days ago
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
Investor's Business Daily 15 days ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire 15 days ago
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
PR Newswire 29 days ago
Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money

Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money
Insider Monkey last month
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
Zacks last month
Biotech stocks slide as Marks resignation seen being negative for sector

Biotech stocks slide as Marks resignation seen being negative for sector
TipRanks last month
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
PR Newswire last month
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
PR Newswire last month
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
PR Newswire last month
View More

Related Tickers

ACLX Arcellx, Inc.
51.66
-2.16%
 
DYN Dyne Therapeutics, Inc.
9.32
-6.99%
 
PCVX Vaxcyte, Inc.
29.17
-0.24%
 
KRYS Krystal Biotech, Inc.
136.25
-2.31%
 
CYTK Cytokinetics, Incorporated
32.83
-3.36%
 
PTCT PTC Therapeutics, Inc.
39.93
+10.34%
 
AKRO Akero Therapeutics, Inc.
42.51
+1.17%
 
MRUS Merus N.V.
39.26
-0.48%
 
CRNX Crinetics Pharmaceuticals, Inc.
31.14
+2.03%
 
BBIO BridgeBio Pharma, Inc.
36.13
-2.19%